anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The proposed project is an ancillary quality improvement study that intends to prospectively track serum markers of inflammation (C-reactive protein or CRP) and nutrition (pre-albumin) at baseline (within 2-months before conversion from reuse to single use of dialyzers) and at the end of a 6-month follow-up period after the conversion, in maintenance hemodialysis patients. The first 2,500 patients from a potential pool of \~2,900 patients from 48 dialysis units that are scheduled to convert from reuse to single use of dialyzers, will be included in the study. Apart from routine monthly laboratory measurements, the investigators, in collaboration with Spectra Laboratories (central lab) will perform measurements of CRP and pre-albumin on the excess blood (after all the routine blood chemistries have been obtained) from the patients selected to be part of the study cohort. It is anticipated that the nature of this study as a quality improvement project, with no additional burden to the patients since tests will only be performed on excess blood from samples already sent to the laboratory, and the utilization of the information only in aggregate with no identifiable personal health information will allow for this study to proceed without the need for informed consent from each individual patient. It is hypothesized that the survival benefit that has been observed in some epidemiological studies (including the prior experience at Fresenius Medical Care, North America) may be accompanied by and/or the result of, reduced inflammation and/or improvement of nutritional status in patients that are converted from reuse to single use of dialyzers. The study will compare the difference between the values of CRP and pre-albumin separately, at baseline and at the end of 6-months after the conversion. CRP levels are expected to decline while pre-albumin are expected to increase during the follow-up period. Even with a 20% dropout rate, the study is expected to have \>90% power to detect a change in CRP of \>3 mg/L and \>99% power to detect a similar change in pre-albumin. The patients in this study are only a subset of a larger epidemiological study that will examine the impact of converting from reuse to single use of dialyzers on patient survival.
PURPOSE:To obtain the title substance by allowing an acylating agent to act on 6-acyl-7-deacetylforskolin derivative into a 1,6,7-triacyl derivative (a novel substance), then removing the acyl group in the 1-position by solvolysis. CONSTITUTION:An acylating agent such as acetic anhydride (2-4 fold moles) is allowed to act on a compound of formula I (R<2> is acyl; R<3> is 2-3C hydrocar bon group) at 0 deg.C to room temperature for several minutes to 2hr to form 1,6,7-triacyl-7-deacetylforskolin derivative (a novel substance) of formula II. Then, the product is preferably hydrolyzed to give a compound of formula III. The hydrolysis is carried out in a solvent in the presence of a base or acid at 0 deg.C to room temperature for 5min-3hr. The solvent is preferably an aqueous alcohol of 1-4C carbon atoms, containing 0.5-20V/V% of water. Thus, the compound of formula III which is expectantly used as a medicines is obtained in high yield.
This is a retrospective cohort study conducted in Hunan Cancer Hospital. Patients (pts) with mCRC who had received at least the 2nd line treatment were eligible. Propensity score (PS) would be calculated to balance the baseline characteristics of two arms. Overall survival (OS) was set as the primary endpoint. From July 2019 to October 2022, 106 eligible pts in total were enrolled. According to the treatment received, 72 and 34 pts were respectively allocated into FP cohort and TB cohort.
This study aimed to examine the effect of yoga on mindfulness and perceived stress levels in nursing students in a parallel-group pretest-posttest randomized controlled study design. The required institutional permission and ethics committee approval was received.

The study was conducted in a nursing department in western Turkey between September 2019 and January 2020. The study consisted of 56 nursing students with (intervention group (n:29), control group (n:27). The intervention group received the yoga program for 15 weeks delivered once a week face to face. The control group did not practice yoga. The data were collected using "Personnel data form", "Mindful Attention Awareness Scale", "Perceived Stress Scale". The data were collected from the students using the online survey. For data analysis, descriptive statistics, paired sample t test, independent t, Pearson chi-square test were used. At the end of the study, the same yoga session was held with the students in the control group.
PURPOSE:To provide a skin-beautifying cosmetic containing an antihistaminic agent, having allergy-suppressing action, exhibiting remarkable effect against chromatosis, applicable continuously over a long period and having high safety. CONSTITUTION:The objective skin-beautifying cosmetic contains an antihistaminic agent such as diphenhydramine hydrochloride, diphenhydramine salicylate or diphenhydramine tannate. The present composition further contains one or more components selected from a mast cell degranulation suppressing agent (e.g. tranilast or sodium cromoglycate), a cyclooxygenase inhibitor (e.g. bufexamac or bendazac) and lipoxygenase inhibitor (e.g. 5,6-dehydroarachidonic acid) as active components. The amount of the essential component in the whole composition is 0.001-50wt.%, preferably 0.1-10wt.%.
ASCEND combines computer-based cognitive training exercises, homework exercises to enhance cognition, and coaching sessions delivered in-person and via telephone/videoconference by a neuropsychologist. ASCEND includes 24 total computer training sessions of 30 minutes each, for a total of 12 hours. ASCEND includes 8 coaching sessions of 45 minutes each. The computer exercises aim to improve attention, working memory (WM), and cognitive control through a series of engaging and interactive computer games (e.g., card games, driving simulation). The homework exercises and coaching sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to daily life and to develop further strategies to compensate for attention and WM difficulties in daily life.
FIELD: cosmetics. SUBSTANCE: the suggested cosmetic preparation contains nutritive, fatty, moisturizing, softening, surface-active, conditioning substances, thickening agent, viscosity regulator, alcohol, scent, conservant; additionally, it contains system out of ceramides and linen glycerol-glycol-water biocomplex, components are taken in certain quantitative content. Cosmetic preparation provides high efficiency of impact onto skin which becomes dense and elastic. It simultaneously nourishes skin. EFFECT: higher efficiency of skin care. 2 cl, 4 ex
Chronic painful intervertebral disc (IVD) degeneration (i.e., discogenic pain) is a major source of global disability needing improved knowledge on multiple-tissue interactions and how they progress in order improve treatment strategies. This study used an in vivo rat annulus fibrosus (AF) injury-driven discogenic pain model to investigate the acute and chronic changes in IVD degeneration and spinal inflammation, as well as sensitization, inflammation, and remodeling in dorsal root ganglion (DRG) and spinal cord (SC) dorsal horn. AF injury induced moderate IVD degeneration with acute and broad spinal inflammation that progressed to DRG to SC changes within days and weeks, respectively. Specifically, AF injury elevated macrophages in the spine (CD68) and DRGs (Iba1) that peaked at 3 days post-injury, and increased microglia (Iba1) in SC that peaked at 2 weeks post-injury. AF injury also triggered glial responses with elevated GFAP in DRGs and SC at least 8 weeks post-injury. Spinal CD68 and SC neuropeptide Substance P both remained elevated at 8 weeks, suggesting that slow and incomplete IVD healing provides a chronic source of inflammation with continued SC sensitization. We conclude that AF injury-driven IVD degeneration induces acute spinal, DRG, and SC inflammatory crosstalk with sustained glial responses in both DRGs and SC, leading to chronic SC sensitization and neural plasticity. The known association of these markers with neuropathic pain suggests that therapeutic strategies for discogenic pain need to target both spinal and nervous systems, with early strategies managing acute inflammatory processes, and late strategies targeting chronic IVD inflammation, SC sensitization, and remodeling.
The outcome of certain plant-virus interaction is symptom recovery, which is accompanied with the emergence of asymptomatic tissues in which the virus accumulation decreased dramatically. This phenomenon shows the potential to reveal critical molecular factors for controlling viral disease. MicroRNAs act as master regulators in plant growth, development, and immunity. However, the mechanism by which miRNA participates in regulating symptom recovery remains largely unknown. Here, we reported that miR172 was scavenged in the recovered tissue of tobacco mosaic virus (TMV)-infected Nicotiana tabacum plants. Overexpression of miR172 promoted TMV infection, whereas silencing of miR172 inhibited TMV infection. Then, TARGET OF EAT3 (TOE3), an APETALA2 transcription factor, was identified as a downstream target of miR172. Overexpression of NtTOE3 significantly improved plant resistance to TMV infection, while knockout of NtTOE3 facilitated virus infection. Furthermore, transcriptome analysis indicated that TOE3 promoted the expression of defense-related genes, such as KL1 and MLP43. Overexpression of these genes conferred resistance of plant against TMV infection. Importantly, results of dual-luciferase assay, chromatin immunoprecipitation-quantitative PCR, and electrophoretic mobility shift assay proved that TOE3 activated the transcription of KL1 and MLP43 by binding their promoters. Moreover, overexpression of rTOE3 (the miR172-resistant form of TOE3) significantly reduced TMV accumulation compared to the overexpression of TOE3 (the normal form of TOE3) in miR172 overexpressing Nicotiana benthamiana plants. Taken together, our study reveals the pivotal role of miR172/TOE3 module in regulating plant immunity and in the establishment of recovery in virus-infected tobacco plants, elucidating a regulatory mechanism integrating plant growth, development, and immune response.
A system and a method are described for scheduling appointments for e.g. patients in medical institutions for performing a procedure such as an examination, according to operational constraints and availability preference criteria. A problem arises when a user of the system gets only one or more available time slots for the appointment, having the duration of the procedure, instead of all possible solutions for a complete time window. A solution is to provide time segments, having a duration longer than or equal to the time slot, and giving the patient the option to select a start time within one of these time segments. The method may be used in a computer or server system e.g. for scheduling examinations of patients in a radiology department or for documentation purposes of these examinations.
We aimed to investigate the correlation between the serum D-dimer (D-D) to albumin (ALB) ratio (DAR) and 28-day all-cause mortality in patients with sepsis. Data from sepsis patients admitted to the intensive care unit (ICU) of Wuhan Fourth Hospital from October 2021 to January 2024 were collected. Univariate cox analysis was performed for mortality factors in sepsis patients, and multiple cox regression models were used to analyze independent mortality risk factors. The receiver operating characteristics (ROC) curve was used to analyze the value of DAR in predicting sepsis mortality, and the Kaplan-Meier method was used to plot the survival curve. A total of 833 patients with sepsis in the ICU of our hospital were selected and divided into alive group (n = 574) and death group (n = 171) according to their 28-day survival. In the death group, D-D and DAR levels were higher, while ALB levels was lower than in the alive group. Spearman analysis found that DAR level were positively correlated with APACHE II and SOFA scores. Multivariate cox regression analysis showed that DAR was an independent predictor of all-cause mortality within 28 days of admission for sepsis patients (HR = 17.956, 95% CI 3.435-93.851, p < 0.001). The ROC curve results showed that the cut-off value of DAR was 0.068, with a sensitivity of 78.4% and a Youden index of 0.375, predicting mortality in sepsis patients, with an area under curve (AUC) of 0.767 (95% CI 0.744-0.790, P < 0.001). Further analysis divided patients into low DAR (DAR < 0.068) and high DAR (DA ≥ 0.068) groups based on the optimal cut-off value. Kaplan-Meier analysis found higher mortality in the high DAR group. DAR is an independent predictor of all-cause mortality within 28 days of admission in sepsis patients. Combining these two indicators can improve clinical treatment guidance and reduce the risk of death.
PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. The inventors questioned this concept, by mapping differential isoform-specific downstream signalling in response to their constant selective inhibition in pancreatic cancer, a disease currently without therapy. They identified common and specific signals activated by each PI3K isoform. These data make the rational for the development of highly selective PI3K isoform drugs used in combination, instead of compounds inhibiting all PI3Ks. In particular, the inventors showed that combined p110a and 110γ inhibition is the most efficient strategy for pancreatic cancer patients.
The BSE Group will receive 50 µmmol/day of sulforaphane administered by BSE (Lantmännen®) from week 0 to week 4. If no side-effects are reported, the sulforaphane dose will increase to 100 µmmol/day from week 5 to week 8 and in the absence of side-effects, the dose will increase to 150 µmmol/day from week 9 to week 12.
PROBLEM TO BE SOLVED: To obtain an adhesive sticking a tray to an impression material when taking impression by using a metallic plate-like tray and an alginate impression material in dentistry field. SOLUTION: This adhesive is obtained by dissolving or suspending. 0.1-30 pts.wt. an alkaline earth metal compound such as calcium hydroxide, magnesium hydroxide, strontium hydroxide, calcium chloride and magnesium chloride in 100 pts.wt. water or an organic solvent such as an alcohol and a ketone, and dispersing 0.05-5 pts.wt. fine particles such as an ultrafine particle silica or an ultrafine particle alumina having <=1 μm average particle diameter.
Patients receive PBF-1129 PO QD and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Charged nutritive proteins provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.
During this TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will take pressure readings after being placed. After four hours, subjects will again be given a second meal. Fifteen minutes of electrical stimulation will be given to subjects fifteen minutes before ingestion of lunch. After ingestion of lunch, 60 minutes of the electrical stimulation will be applied. When the test is done, the tube will be removed.
The present inventors found that the indolinone compound of the present invention has excellent effect of activating nerve cells. The present inventors further found that the function mechanism of the effect of activating nerve cells is based on the promotion of the expression of a protein that relates to the BDNF signaling system and/or the VEGF signaling system. Thus, the indolinone compound of the present invention is usable as a therapeutic agent for various neuropsychiatric diseases. Moreover, this compound can protect transplanted neural progenitor cells and, therefore, is usable as an adjunct in regenerative medicine.　The present inventors established a method for inducing the differentiation of induced pluripotent stem cells (iPS cells) into nerve cells at a high efficiency without through the formation of an embryonic body (cell aggregate) in a xeno-free culture system. By this method, nerve cells, which contained no factor derived from a different organism, were affected neither by unidentified components nor by interlot differences and had characteristics of a disease patient, were successfully prepared. As a result, it becomes possible to stably screen and analyze a compound for the treatment of a neurological disease for drug discovery.
BACKGROUND: The World Falls Guidelines (WFG) propose an algorithm that classifies patients as low-, intermediate-, and high-risk. We evaluated different operationalizations of the WFG algorithm and compared its predictive performance to other screening tools for falls, namely: the American Geriatrics Society and British Geriatrics Society (AGS/BGS) algorithm, the 3KQ on their own and fall history on its own.
METHODS: We included data from 1509 adults aged ≥65 years from the population-based Longitudinal Aging Study Amsterdam. The outcome was ≥1 fall during 1-year follow-up, which was ascertained using fall calendars. The screening tools' items were retrospectively operationalized using baseline measures, using proxies where necessary.
RESULTS: Sensitivity ranged between 30.9-48.0% and specificity ranged between 77.0-88.2%. Operationalizing the algorithm with the 3KQ instead of fall history yielded a higher sensitivity but lower specificity, whereas operationalization with the Clinical Frailty Scale (CFS) classification tree instead of Fried's frailty criteria did not affect predictive performance. Compared to the WFG algorithm, the AGS/BGS algorithm and fall history on its own yielded similar predictive performance, whereas the 3KQ on their own yielded a higher sensitivity but lower specificity.
CONCLUSION: The WFG algorithm can identify patients at risk of a fall, especially when the 3KQ are included in its operationalization. The CFS and Fried's frailty criteria may be used interchangeably in the algorithm's operationalization. The algorithm performed similarly compared to other screening tools, except for the 3KQ on their own, which have higher sensitivity but lower specificity and lack clinical recommendations per risk category.
PCT No. PCT/FI97/00448 Sec. 371 Date Jan. 15, 1999 Sec. 102(e) Date Jan. 15, 1999 PCT Filed Jul. 16, 1997 PCT Pub. No. WO98/03165 PCT Pub. Date Jan. 29, 1998A method of treating respiratory infections or complications derived therefrom in mammals, especially acute otitis media in humans, which includes administering to the mammal an effective amount of xylitol. The invention further concerns the use of xylitol for the preparation of a pharmaceutical composition for the treatment of respiratory infections or complications derived therefrom in mammals. One or more therapeutically active agents may optionally be added to the pharmaceutical composition, which can be a solid preparation, such as chewing gum, a powder or tablet, or a liquid preparation.
A sustained and/or delayed release pharmaceutical tablet comprises a solid medicinally active substance, e.g. a solid "drug" or a drug admixed with a solid carrier in admixture with and/or coated with a water-insoluble copolymer of an olefinically unsaturated carboxylic acid monomer (e.g. acrylic acid) cross-linked with from 1 to 2% of a polyalkenyl polyether, e.g. "Carbopol" (Registered Trade Mark) 934. Mixing the polymer and drug and pressing into a tablet (optionally after slugging and grinding) gives a sustained release tablet which may be coated with the polymer to give an enteric tablet with sustained release. Coating a conventional tablet core with the polymer gives an enteric tablet.  Suitable drugs which are preferably an acid or a salt are analgesics, antispasmodics, hypertensive agents, muscle relaxants, ataractics, antibiotics, anticonvulsants, antihistamines, coronary and peripheral vasodilators, fungistatic agents, antinauseants, central nervous system stimulants, parasympathetic inhibitors, antipruritics and phenothiazine compounds, specific examples being: mephentermine sulphate, promazine hydrochloride, potassium phenoxymethyl penicillin, ergotamine tartrate, acetylsalicylic acid, sodium salicylate and aminophylline.
This is a single arm prospective study. All eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel, followed by hypofractionated radiation therapy followed by surgical resection. Subjects may receive adjuvant chemotherapy post surgical resection at the clinical discretion of the medical oncologist.
Transcranial magnetic stimulation (TMS) will be administrated with a figure-8 coil over the left dorsolateral prefrontal cortex (DLPFC) at the intensity of up to 120% of the individualized resting motor threshold (rMT). Stimulation will be performed during and for the duration of the cognitive test. Up to three TMS pulses will be delivered at the beginning of every test trial (each trial duration is 2-6 seconds). The total duration of the cognitive testing and stimulation per session is approximately 40 minutes (in 4 blocks with breaks in-between).